CAT and cancer: In this study, doses of ProB, CAT, ProB2 plus DOCE or CAT plus DOCE, with minimal impact on the viability of healthy breast or prostate cells (viability ranging from 96 to 98%), drastically decreased viability in PC and BC cancer cells (viability between 73% and 45%, depending on the compound and cell type).